Schatz & Nobel, P.C. Announces Class Action Lawsuit Against Biovail Corporation and Others

Schatz & Nobel, P.C. Announces Class Action Lawsuit Against Biovail Corporation
and Others 


HARTFORD, Conn., Nov. 13  /PRNewswire/ -- A lawsuit seeking class action status
has been filed in the United States District Court for the Southern District of
New York on behalf of all persons who purchased the common shares of Biovail
Corporation (NYSE: BVF; TSX: BVF) ("Biovail" or the "Company") between February
7, 2003 and October 30, 2003 (the "Class Period" or the "Class") for violations
of the federal securities laws.  Biovail's common shares are traded on the New
York Stock Exchange and on the Toronto Stock Exchange under the symbol "BVF."

Plaintiff is represented by the law firm of Schatz & Nobel, P.C., which has
significant experience prosecuting class actions on behalf of investors. If you
wish to discuss this action or have any questions, please contact attorney
Andrew M. Schatz, Jeffrey S. Nobel, or Nancy A. Kulesa at (800) 797- 5499, or by
e-mail at .  For more information about Schatz & Nobel, P.C. and class action
cases, please visit our website: http://www.snlaw.net/.

The Complaint alleges that Biovail and certain of its officers and directors
made materially false and misleading statements during the Class Period. 
Specifically, Defendants made material misrepresentations concerning Biovail's
financial results and business by, inter alia, improperly reporting revenue and
earnings attributable to the sales of a generic version of Prilosec and
misstating the demand in the marketplace for that product. Plaintiff further
alleges that these material misrepresentations artificially inflated the price
of Biovail's common shares, which traded as high as $50.30 on the New York Stock
Exchange and as high as CD $67.75 on the Toronto Stock Exchange during the Class
Period.

Plaintiff seeks to recover damages on behalf of all Class Members, including
Class Members that purchased Biovail common shares on the Toronto Stock
Exchange.  If you purchased or otherwise acquired Biovail common shares between
February 7, 2003 and October 30, 2003, and wish to act as a lead plaintiff, you
may move the Court to act in that capacity not later than January 12, 2004.  If
you wish to discuss your rights as lead plaintiff or as a class member, please
contact Schatz & Nobel, P.C. toll-free at (800) 797- 5499, or by e-mail at .

  CONTACT:   Andrew M. Schatz
             Jeffrey S. Nobel
             Nancy A. Kulesa
             Tel.: [phone]
             Website: http://www.snlaw.net/
             e-mail: 

DATASOURCE: Schatz & Nobel, P.C.



CONTACT:  Andrew M. Schatz, Jeffrey S. Nobel or Nancy A. Kulesa, all of

Schatz & Nobel, P.C., [phone], 



Web site:  http://www.snlaw.net/

Copyright